Rizatriptan Tablet, Film Coated
Product Images NDC 71335-1352

5 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rizatriptan (NDC 71335-1352). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Rizatriptan Structure One)

1 (Rizatriptan Structure One)
Chemical structure of the active ingredient Rizatriptan, depicting its molecular arrangement including a triazole ring, an indole moiety, and a benzoic acid group.*
FDA Label Image

1 (Rizatriptan Figure One)

1 (Rizatriptan Figure One)
Line graph depicting the estimated probability of response over hours post-dose for placebo, Rizatriptan Benzoate Tablets 5 mg, and Rizatriptan Benzoate Tablets 10 mg. The x-axis shows time in hours post-dose (0 to 2), and the y-axis shows estimated probability of response (0% to 100%). Both Rizatriptan doses show higher response probabilities than placebo, increasing over time.*
FDA Label Image

1 (Rizatriptan Figure Two)

1 (Rizatriptan Figure Two)
A line graph showing the estimated probability of remediation or rescue over 24 hours post-dose for placebo, Rizatriptan Benzoate Tablets 5 mg, and 10 mg. The x-axis represents hours post-dose from 0 to 24, and the y-axis shows the estimated probability from 0% to 100%. Lines indicate increasing probabilities over time, with placebo showing the highest curve, followed by the 5 mg and 10 mg Rizatriptan Benzoate tablet lines.*
FDA Label Image

Fig-5 (Rizatriptan Fct Figure 5)

Fig-5 (Rizatriptan Fct Figure 5)
A line graph comparing the percent effect over hours post stage 2 dose between Rizatriptan Benzoate Orally Disintegrating Tablets and placebo. The x-axis represents hours post dose (0.5 to 2 hours), and the y-axis represents percent with 95% confidence intervals. Rizatriptan shows a higher percent effect compared to placebo over time.*
FDA Label Image

Label (Lbl713351352)

Label (Lbl713351352)
Label for Rizatriptan Benzoate 10 mg tablet in blister packaging by Bryant Ranch Prepack. The label indicates it compares to Maxalt 10 mg tablet from Macleods Pharmaceuticals Ltd. The package contains 10 tablets with NDC 71335-1352. Storage instructions recommend room temperature 20°-25°C (68°-77°F). The label also includes a barcode and a caution to keep drugs out of children's reach.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.